Role of the hypothalamus in the neuroendocrine regulation of body weight and composition during energy deficit

Obesity Reviews

Volumn 13, Issue 3, 2012, Pages 234-257

  Sainsbury, A ^a,b,c   Zhang, L ^a  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Corticotropic axis; Gonadotropic axis; Somatotropic axis; Thyrotropic axis

Indexed keywords

CORTICOTROPIN; GLUCOCORTICOID; HYDROCORTISONE; LIOTHYRONINE; MESSENGER RNA; NEUROPEPTIDE Y; PROTIRELIN; SOMATOMEDIN C; THYROXINE;

ANOREXIA NERVOSA; APPETITE; ARTICLE; BODY COMPOSITION; BODY FAT DISTRIBUTION; BODY WEIGHT; CIRCADIAN RHYTHM; DISEASE ASSOCIATION; ENERGY BALANCE; ENERGY DEFICIT; FEEDBACK SYSTEM; HORMONAL REGULATION; HORMONE ACTION; HORMONE RELEASE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOPHYSIS GONAD SYSTEM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS THYROID SYSTEM; HYPOTHYROIDISM; MALNUTRITION; METABOLIC ACTIVATION; METABOLIC INHIBITION; METABOLIC REGULATION; NONHUMAN; OBESITY; THYROID FUNCTION; THYROID HORMONE METABOLISM; WEIGHT REDUCTION;

ADIPOSE TISSUE; ANIMALS; APPETITE; BODY COMPOSITION; BODY WEIGHT; DISEASE MODELS, ANIMAL; ENERGY INTAKE; ENERGY METABOLISM; FASTING; HUMANS; HYPOTHALAMUS; LEPTIN; NEUROPEPTIDES;

EID: 84857191466     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/j.1467-789X.2011.00948.x     Document Type: Article

References (258)

1. Martin CK, Heilbronn LK, de Jonge L, DeLany JP, Volaufova J, Anton SD etal. Effect of calorie restriction on resting metabolic rate and spontaneous physical activity. Obesity 2007; 15: 2964-2973.
2. Sullivan EL, Cameron JL. A rapidly occurring compensatory decrease in physical activity counteracts diet-induced weight loss in female monkeys. Am J Physiol Regul Integr Comp Physiol 2010; 298: R1068-R1074.
3. Martin CK, Das SK, Lindblad L, Racette SB, McCrory MA, Weiss EP etal. Effect of calorie restriction on the free-living physical activity levels of nonobese humans: results of three randomized trials. J Appl Physiol 2011; 110: 956-963.
4. Rosenbaum M, Vandenborne K, Goldsmith R, Simoneau JA, Heymsfield S, Joanisse DR etal. Effects of experimental weight perturbation on skeletal muscle work efficiency in human subjects. Am J Physiol Regul Integr Comp Physiol 2003; 285: R183-R192.
5. Smith DL Jr, Nagy TR, Allison DB. Calorie restriction: what recent results suggest for the future of ageing research. Eur J Clin Invest 2010; 40: 440-450.
6. Sainsbury A, Zhang L. Role of the arcuate nucleus of the hypothalamus in regulation of body weight during energy deficit. Mol Cell Endocrinol 2010; 316: 109-119.
7. Novak CM, Levine JA. Central neural and endocrine mechanisms of non-exercise activity thermogenesis and their potential impact on obesity. J Neuroendocrinol 2007; 19: 923-940.
8. Keys A, Brozek J, Henschel A, Mickelsen O, Taylor HL. The Biology of Human Starvation. University of Minnesota Press: Minneapolis, MN, 1950.
9. Doucet E, Imbeault P, St-Pierre S, Almeras N, Mauriege P, Richard D etal. Appetite after weight loss by energy restriction and a low-fat diet-exercise follow-up. Int J Obes Relat Metab Disord 2000; 24: 906-914.
10. Westerterp-Plantenga MS, Saris WH, Hukshorn CJ, Campfield LA. Effects of weekly administration of pegylated recombinant human OB protein on appetite profile and energy metabolism in obese men. Am J Clin Nutr 2001; 74: 426-434.
11. Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med 1995; 332: 621-628.
12. Hukshorn CJ, Menheere PP, Westerterp-Plantenga MS, Saris WH. The effect of pegylated human recombinant leptin (PEG-OB) on neuroendocrine adaptations to semi-starvation in overweight men. Eur J Endocrinol 2003; 148: 649-655.
13. Pasman WJ, Saris WH, Westerterp-Plantenga MS. Predictors of weight maintenance. Obes Res 1999; 7: 43-50.
14. MacLean PS, Higgins JA, Johnson GC, Fleming-Elder BK, Peters JC, Hill JO. Metabolic adjustments with the development, treatment, and recurrence of obesity in obesity-prone rats. Am J Physiol Regul Integr Comp Physiol 2004; 287: R288-R297.
15. Goran MI. Energy metabolism and obesity. Med Clin North Am 2000; 84: 347-362.
16. Dulloo AG, Girardier L. Adaptive changes in energy expenditure during refeeding following low-calorie intake: evidence for a specific metabolic component favoring fat storage. Am J Clin Nutr 1990; 52: 415-420.
17. Kalra SP, Dube MG, Pu SY, Xu B, Horvath TL, Kalra PS. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr Rev 1999; 20: 68-100.
18. Olszewski PK, Klockars A, Schioth HB, Levine AS. Oxytocin as feeding inhibitor: maintaining homeostasis in consummatory behavior. Pharmacol Biochem Behav 2010; 97: 47-54.
19. Stanley BG, Chin AS, Leibowitz SF. Feeding and drinking elicited by central injection of neuropeptide Y: evidence for a hypothalamic site(s) of action. Brain Res Bull 1985; 14: 521-524.
20. Clark JT, Kalra PS, Crowley WR, Kalra SP. Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. Endocrinology 1984; 115: 427-429.
21. Bai FL, Yamano M, Shiotani Y, Emson PC, Smith AD, Powell JF etal. An arcuato-paraventricular and -dorsomedial hypothalamic neuropeptide Y-containing system which lacks noradrenaline in the rat. Brain Res 1985; 331: 172-175.
22. Yulyaningsih E, Zhang L, Herzog H, Sainsbury A. NPY receptors as potential targets for anti-obesity drug development. Br J Pharmacol 2011; 163: 1170-1202.
23. Ollmann MM, Wilson BD, Yang YK, Kerns JA, Chen Y, Gantz I etal. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein [published erratum appears in Science 1998 Sep 11;281(5383):1615]. Science 1997; 278: 135-138.
24. Cone RD. Studies on the physiological functions of the melanocortin system. Endocr Rev 2006; 27: 736-749.
25. Elias CF, Saper CB, Maratos-Flier E, Tritos NA, Lee C, Kelly J etal. Chemically defined projections linking the mediobasal hypothalamus and the lateral hypothalamic area. J Comp Neurol 1998; 402: 442-459.
26. Mountjoy KG, Robbins LS, Mortrud MT, Cone RD. The cloning of a family of genes that encode the melanocortin receptors. Science 1992; 257: 1248-1251.
27. Adan RA, Cone RD, Burbach JP, Gispen WH. Differential effects of melanocortin peptides on neural melanocortin receptors. Mol Pharmacol 1994; 46: 1182-1190.
28. Baker RA, Herkenham M. Arcuate nucleus neurons that project to the hypothalamic paraventricular nucleus: neuropeptidergic identity and consequences of adrenalectomy on mRNA levels in the rat. J Comp Neurol 1995; 358: 518-530.
29. O'Donohue TL, Miller RL, Jacobowitz DM. Identification, characterization and stereotaxic mapping of intraneuronal alpha-melanocyte stimulating hormone-like immunoreactive peptides in discrete regions of the rat brain. Brain Res 1979; 176: 101-123.
30. Thiele TE, van Dijk G, Yagaloff KA, Fisher SL, Schwartz M, Burn P etal. Central infusion of melanocortin agonist MTII in rats: assessment of c-Fos expression and taste aversion. Am J Physiol 1998; 274: R248-R254.
31. Brown KS, Gentry RM, Rowland NE. Central injection in rats of alpha-melanocyte-stimulating hormone analog: effects on food intake and brain Fos. Regul Pept Suppl 1998; 78: 89-94.
32. Murphy KG. Dissecting the role of cocaine- and amphetamine-regulated transcript (CART) in the control of appetite. Brief Funct Genomic Proteomic 2005; 4: 95-111.
33. Blake NG, Johnson MR, Eckland DJ, Foster OJ, Lightman SL. Effect of food deprivation and altered thyroid status on the hypothalamic-pituitary-thyroid axis in the rat. J Endocrinol 1992; 133: 183-188.
34. Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E etal. Role of leptin in the neuroendocrine response to fasting. Nature 1996; 382: 250-252.
35. Boelen A, Kwakkel J, Vos XG, Wiersinga WM, Fliers E. Differential effects of leptin and refeeding on the fasting-induced decrease of pituitary type 2 deiodinase and thyroid hormone receptor beta2 mRNA expression in mice. J Endocrinol 2006; 190: 537-544.
36. Bakker O, Razaki H, de Jong J, Ris-Stalpers C, Wiersinga WM. Expression of the alpha 1, alpha 2, and beta 1 T3-receptor mRNAs in the fasted rat measured using competitive PCR. Biochem Biophys Res Commun 1998; 242: 492-496.
37. Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 2002; 23: 38-89.
38. Hernandez A, St Germain DL. Thyroid hormone deiodinases: physiology and clinical disorders. Curr Opin Pediatr 2003; 15: 416-420.
39. Aceves C, Escobar C, Rojas-Huidobro R, Vazquez-Martinez O, Martinez-Merlos T, Aguilar-Roblero R etal. Liver 5′-deiodinase activity is modified in rats under restricted feeding schedules: evidence for post-translational regulation. J Endocrinol 2003; 179: 91-96.
40. Gavin LA, Bui F, McMahon F, Cavalieri RR. Sequential deiodination of thyroxine to 3, 3′-diiodothyronine via 3, 5, 3′-triiodothyronine and 3, 3′, 5′-triiodothyronine in rat liver homogenate. The effects of fasting versus glucose feeding. J Biol Chem 1980; 255: 49-54.
41. Diano S, Naftolin F, Goglia F, Horvath TL. Segregation of the intra- and extrahypothalamic neuropeptide Y and catecholaminergic inputs on paraventricular neurons, including those producing thyrotropin-releasing hormone. Regul Pept 1998; 75-76: 117-126.
42. Coppola A, Hughes J, Esposito E, Schiavo L, Meli R, Diano S. Suppression of hypothalamic deiodinase type II activity blunts TRH mRNA decline during fasting. FEBS Lett 2005; 579: 4654-4658.
43. Coppola A, Liu ZW, Andrews ZB, Paradis E, Roy MC, Friedman JM etal. A central thermogenic-like mechanism in feeding regulation: an interplay between arcuate nucleus T3 and UCP2. Cell Metab 2007; 5: 21-33.
44. Boelen A, Wiersinga WM, Fliers E. Fasting-induced changes in the hypothalamus-pituitary-thyroid axis. Thyroid 2008; 18: 123-129.
45. Warren MP. Endocrine manifestations of eating disorders. J Clin Endocrinol Metab 2011; 96: 333-343.
46. Mastorakos G, Pavlatou M. Exercise as a stress model and the interplay between the hypothalamus-pituitary-adrenal and the hypothalamus-pituitary-thyroid axes. Horm Metab Res 2005; 37: 577-584.
47. Kanaka-Gantenbein C. The impact of exercise on thyroid hormone metabolism in children and adolescents. Horm Metab Res 2005; 37: 563-565.
48. Reinehr T. Obesity and thyroid function. Mol Cell Endocrinol 2010; 316: 165-171.
49. Kozlowska L, Rosolowska-Huszcz D. Leptin, thyrotropin, and thyroid hormones in obese/overweight women before and after two levels of energy deficit. Endocrine 2004; 24: 147-153.
50. Rosenbaum M, Hirsch J, Murphy E, Leibel RL. Effects of changes in body weight on carbohydrate metabolism, catecholamine excretion, and thyroid function. Am J Clin Nutr 2000; 71: 1421-1432.
51. Weinsier RL, Nagy TR, Hunter GR, Darnell BE, Hensrud DD, Weiss HL. Do adaptive changes in metabolic rate favor weight regain in weight-reduced individuals? An examination of the set-point theory. Am J Clin Nutr 2000; 72: 1088-1094.
52. Wadden TA, Mason G, Foster GD, Stunkard AJ, Prange AJ. Effects of a very low calorie diet on weight, thyroid hormones and mood. Int J Obes 1990; 14: 249-258.
53. Naslund E, Andersson I, Degerblad M, Kogner P, Kral JG, Rossner S etal. Associations of leptin, insulin resistance and thyroid function with long-term weight loss in dieting obese men. J Int Med 2000; 248: 299-308.
54. Douyon L, Schteingart DE. Effect of obesity and starvation on thyroid hormone, growth hormone, and cortisol secretion. Endocrinol Metab Clin North Am 2002; 31: 173-189.
55. Fekete C, Kelly J, Mihaly E, Sarkar S, Rand WM, Legradi G etal. Neuropeptide Y has a central inhibitory action on the hypothalamic-pituitary-thyroid axis. Endocrinology 2001; 142: 2606-2613.
56. Small CJ, Kim MS, Stanley SA, Mitchell JRD, Murphy K, Morgan DGA etal. Effects of chronic central nervous system administration of agouti-related protein in pair-fed animals. Diabetes 2001; 50: 248-254.
57. Kim MS, Small CJ, Stanley SA, Morgan DG, Seal LJ, Kong WM etal. The central melanocortin system affects the hypothalamo-pituitary thyroid axis and may mediate the effect of leptin. J Clin Invest 2000; 105: 1005-1011.
58. Legradi G, Lechan RM. Agouti-related protein containing nerve terminals innervate thyrotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Endocrinology 1999; 140: 3643-3652.
59. Legradi G, Lechan RM. The arcuate nucleus is the major source for neuropeptide Y-innervation of thyrotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Endocrinology 1998; 139: 3262-3270.
60. Mihaly E, Fekete C, Tatro JB, Liposits Z, Stopa EG, Lechan RM. Hypophysiotropic thyrotropin-releasing hormone-synthesizing neurons in the human hypothalamus are innervated by neuropeptide Y, agouti-related protein, and alpha-melanocyte-stimulating hormone. J Clin Endocrinol Metab 2000; 85: 2596-2603.
61. Chowdhury I, Chien JT, Chatterjee A, Yu JY. Effects of leptin and neuropeptide-Y on transcript levels of thyrotropin beta and common alpha subunits of rat pituitary cells in vitro. Life Sci 2004; 75: 2897-2909.
62. Kakucska I, Qi Y, Lechan RM. Changes in adrenal status affect hypothalamic thyrotropin-releasing hormone gene expression in parallel with corticotropin-releasing hormone. Endocrinology 1995; 136: 2795-2802.
63. Alkemade A, Unmehopa UA, Wiersinga WM, Swaab DF, Fliers E. Glucocorticoids decrease thyrotropin-releasing hormone messenger ribonucleic acid expression in the paraventricular nucleus of the human hypothalamus. J Clin Endocrinol Metab 2005; 90: 323-327.
64. Nicoloff JT, Fisher DA, Appleman MD Jr. The role of glucocorticoids in the regulation of thyroid function in man. J Clin Invest 1970; 49: 1922-1929.
65. Lee SL, Stewart K, Goodman RH. Structure of the gene encoding rat thyrotropin releasing hormone. J Biol Chem 1988; 263: 16604-16609.
66. Hisano S, Fukui Y, Chikamori-Aoyama M, Aizawa T, Shibasaki T. Reciprocal synaptic relations between CRF-immunoreactive- and TRH-immunoreactive neurons in the paraventricular nucleus of the rat hypothalamus. Brain Res 1993; 620: 343-346.
67. Liao N, Vaudry H, Pelletier G. Neuroanatomical connections between corticotropin-releasing factor (CRF) and somatostatin (SRIF) nerve endings and thyrotropin-releasing hormone (TRH) neurons in the paraventricular nucleus of rat hypothalamus. Peptides 1992; 13: 677-680.
68. Mitsuma T, Nogimori T, Hirooka Y. Effects of growth hormone-releasing hormone and corticotropin-releasing hormone on the release of thyrotropin-releasing hormone from the rat hypothalamus in vitro. Exp Clin Endocrinol 1987; 90: 365-368.
69. de Gortari P, Mancera K, Cote-Velez A, Amaya MI, Martinez A, Jaimes-Hoy L etal. Involvement of CRH-R2 receptor in eating behavior and in the response of the HPT axis in rats subjected to dehydration-induced anorexia. Psychoneuroendocrinology 2009; 34: 259-272.
70. Fekete C, Legradi G, Mihaly E, Huang QH, Tatro JB, Rand WM etal. Alpha-melanocyte-stimulating hormone is contained in nerve terminals innervating thyrotropin-releasing hormone-synthesizing neurons in the hypothalamic paraventricular nucleus and prevents fasting-induced suppression of prothyrotropin-releasing hormone gene expression. J Neurosci 2000; 20: 1550-1558.
71. Fekete C, Mihaly E, Luo LG, Kelly J, Clausen JT, Mao Q etal. Association of cocaine- and amphetamine-regulated transcript-immunoreactive elements with thyrotropin-releasing hormone-synthesizing neurons in the hypothalamic paraventricular nucleus and its role in the regulation of the hypothalamic-pituitary-thyroid axis during fasting. J Neurosci 2000; 20: 9224-9234.
72. Stanley SA, Small CJ, Murphy KG, Rayes E, Abbott CR, Seal LJ etal. Actions of cocaine- and amphetamine-regulated transcript (CART) peptide on regulation of appetite and hypothalamo-pituitary axes in vitro and in vivo in male rats. Brain Res 2001; 893: 186-194.
73. Fekete C, Lechan RM. Neuroendocrine implications for the association between cocaine- and amphetamine regulated transcript (CART) and hypophysiotropic thyrotropin-releasing hormone (TRH). Peptides 2006; 27: 2012-2018.
74. Gysling K, Forray MI, Haeger P, Daza C, Rojas R. Corticotropin-releasing hormone and urocortin: redundant or distinctive functions? Brain Res Brain Res Rev 2004; 47: 116-125.
75. Dunn AJ, Berridge CW. Physiological and behavioral responses to corticotropin-releasing factor administration - is CRF a mediator of anxiety or stress responses. Brain Res Brain Res Rev 1990; 15: 71-100.
76. Erickson JC, Ahima RS, Hollopeter G, Flier JS, Palmiter RD. Endocrine function of neuropeptide Y knockout mice. Regul Pept 1997; 70: 199-202.
77. Fekete C, Legradi G, Mihaly E, Tatro JB, Rand WM, Lechan RM. Alpha-melanocyte stimulating hormone prevents fasting-induced suppression of corticotropin-releasing hormone gene expression in the rat hypothalamic paraventricular nucleus. Neurosci Lett 2000; 289: 152-156.
78. Epling WF, Pierce WD. Activity-based anorexia: a biobehavioral perspective. Int J Eat Disord 1988; 7: 475-485.
79. Burden VR, White BD, Dean RG, Martin RJ. Activity of the hypothalamic-pituitary-adrenal axis is elevated in rats with activity-based anorexia. J Nutr 1993; 123: 1217-1225.
80. Duclos M, Corcuff JB, Roger P, Tabarin A. The dexamethasone-suppressed corticotrophin-releasing hormone stimulation test in anorexia nervosa. Clin Endocrinol (Oxf) 1999; 51: 725-731.
81. Fichter MM, Pirke KM. Effect of experimental and pathological weight loss upon the hypothalamo-pituitary-adrenal axis. Psychoneuroendocrinology 1986; 11: 295-305.
82. Georgopoulos NA, Rottstein L, Tsekouras A, Theodoropoulou A, Koukkou E, Mylonas P etal. Abolished circadian rhythm of salivary cortisol in elite artistic gymnasts. Steroids 2011; 76: 353-357.
83. Friedl KE, Moore RJ, Hoyt RW, Marchitelli LJ, Martinez-Lopez LE, Askew EW. Endocrine markers of semistarvation in healthy lean men in a multistressor environment. J Appl Physiol 2000; 88: 1820-1830.
84. Johnstone AM, Faber P, Andrew R, Gibney ER, Elia M, Lobley G etal. Influence of short-term dietary weight loss on cortisol secretion and metabolism in obese men. Eur J Endocrinol 2004; 150: 185-194.
85. Ho JT, Keogh JB, Bornstein SR, Ehrhart-Bornstein M, Lewis JG, Clifton PM etal. Moderate weight loss reduces renin and aldosterone but does not influence basal or stimulated pituitary-adrenal axis function. Horm Metab Res 2007; 39: 694-699.
86. Guillaume-Gentil C, Assimacopoulos-Jeannet F, Jeanrenaud B. Involvement of non-esterified fatty acid oxidation in glucocorticoid-induced peripheral insulin resistance in vivo in rats. Diabetologia 1993; 36: 899-906.
87. Rebuffe-Scrive M, Walsh UA, McEwen B, Rodin J. Effect of chronic stress and exogenous glucocorticoids on regional fat distribution and metabolism. Physiol Behav 1992; 52: 583-590.
88. Dallman MF, Strack AM, Akana SF, Bradbury MJ, Hanson ES, Scribner KA etal. Feast and famine: critical role of glucocorticoids with insulin in daily energy flow. Front Neuroendocrinol 1993; 14: 303-347.
89. Green PK, Wilkinson CW, Woods SC. Intraventricular corticosterone increases the rate of body weight gain in underweight adrenalectomized rats. Endocrinology 1992; 130: 269-275.
90. Zakrzewska KE, Cusin I, Stricker-Krongrad A, Boss O, Ricquier D, Jeanrenaud B etal. Induction of obesity and hyperleptinemia by central glucocorticoid infusion in the rat. Diabetes 1999; 48: 365-370.
91. McMahon M, Gerich J, Rizza R. Effects of glucocorticoids on carbohydrate metabolism. Diabetes Metab Rev 1988; 4: 17-30.
92. McDonald JK, Koenig JI. Neuropeptide Y actions on reproductive and endocrine functions. In: Colmers WF, Wahlestedt C (eds). The Biology of Neuropeptide Y and Related Peptides. Humana Press Inc: New Jersey, 1993, pp. 419-456.
93. Sainsbury A, Rohner-Jeanrenaud F, Cusin I, Zakrzewska KE, Halban PA, Gaillard RC etal. Chronic central neuropeptide Y infusion in normal rats - status of the hypothalamo-pituitary-adrenal axis, and vagal mediation of hyperinsulinaemia. Diabetologia 1997; 40: 1269-1277.
94. Liposits Z, Sievers L, Paull WK. Neuropeptide-Y and ACTH-immunoreactive innervation of corticotropin releasing factor (CRF)-synthesizing neurons in the hypothalamus of the rat. Histochemistry 1988; 88: 227-234.
95. Small CJ, Todd JF, Ghatei M, Smith DM, Bloom SR. Neuropeptide Y (NPY) actions on the corticotroph cell of the anterior pituitary gland are not mediated by a direct effect. Regul Pept 1998; 75-76: 301-307.
96. Allison SJ, Baldock PA, Enriquez RF, Lin E, During M, Gardiner EM etal. Critical interplay between neuropeptide Y and sex steroid pathways in bone and adipose tissue homeostasis. J Bone Miner Res 2009; 24: 294-304.
97. Sainsbury A, Schwarzer C, Couzens M, Herzog H. Y2 receptor deletion attenuates the type 2 diabetic syndrome of ob/ob mice. Diabetes 2002; 51: 3420-3427.
98. Sainsbury A, Schwarzer C, Couzens M, Jenkins A, Oakes SR, Ormandy CJ etal. Y4 receptor knockout rescues fertility in ob/ob mice. Genes Dev 2002; 16: 1077-1088.
99. Beck B. Neuropeptides and obesity. Nutrition 2000; 16: 916-923.
100. Kakui N, Kitamura K. Direct evidence that stimulation of neuropeptide Y Y5 receptor activates hypothalamo-pituitary-adrenal axis in conscious rats via both corticotropin-releasing factor- and arginine vasopressin-dependent pathway. Endocrinology 2007; 148: 2854-2862.
101. Lu XY, Barsh GS, Akil H, Watson SJ. Interaction between alpha-melanocyte-stimulating hormone and corticotropin-releasing hormone in the regulation of feeding and hypothalamo-pituitary-adrenal responses. J Neurosci 2003; 23: 7863-7872.
102. Dhillo WS, Small CJ, Seal LJ, Kim MS, Stanley SA, Murphy KG etal. The hypothalamic melanocortin system stimulates the hypothalamo-pituitary-adrenal axis in vitro and in vivo in male rats. Neuroendocrinology 2002; 75: 209-216.
103. Preston E, Cooney GJ, Wilks D, Baran K, Zhang L, Kraegen EW etal. Central neuropeptide Y infusion and melanocortin 4 receptor antagonism inhibit thyrotropic function by divergent pathways. Neuropeptides 2011. doi: 10.1016/j.npep.2011.07.009.
104. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR etal. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997; 88: 131-141.
105. Baran K, Preston E, Wilks D, Cooney GJ, Kraegen EW, Sainsbury A. Chronic central melanocortin-4 receptor antagonismand central neuropeptide-Y infusion in rats produce increased adiposity by divergent pathways. Diabetes 2002; 51: 152-158.
106. Kristensen P, Judge ME, Thim L, Ribel U, Christjansen KN, Wulff BS etal. Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 1998; 393: 72-76.
107. Wang C, Billington CJ, Levine AS, Kotz CM. Effect of CART in the hypothalamic paraventricular nucleus on feeding and uncoupling protein gene expression. Neuroreport 2000; 11: 3251-3255.
108. Kong WM, Stanley S, Gardiner J, Abbott C, Murphy K, Seth A etal. A role for arcuate cocaine and amphetamine-regulated transcript in hyperphagia, thermogenesis, and cold adaptation. FASEB J 2003; 17: 1688-1690.
109. Lechan RM, Fekete C. The TRH neuron: a hypothalamic integrator of energy metabolism. Prog Brain Res 2006; 153: 209-235.
110. Vrang N, Larsen PJ, Kristensen P, Tang-Christensen M. Central administration of cocaine-amphetamine-regulated transcript activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 2000; 141: 794-801.
111. Baranowska B, Wolinska-Witort E, Bik W, Baranowska-Bik A, Martynska L, Chmielowska M. The effect of cocaine-amphetamine regulated transcript (CART) on the activation of the pituitary-adrenal axis. Neuro Endocrinol Lett 2006; 27: 60-62.
112. Wade GN, Schneider JE, Li HY. Control of fertility by metabolic cues. Am J Physiol 1996; 270: E1-E19.
113. Li C, Chen P, Smith MS. Morphological evidence for direct interaction between arcuate nucleus neuropeptide Y (NPY) neurons and gonadotropin-releasing hormone neurons and the possible involvement of NPY Y1 receptors. Endocrinology 1999; 140: 5382-5390.
114. Standish LJ, Adams LA, Vician L, Clifton DK, Steiner RA. Neuroanatomical localization of cells containing gonadotropin-releasing hormone messenger ribonucleic acid in the primate brain by in situ hybridization histochemistry. Mol Endocrinol 1987; 1: 371-376.
115. Burchanowski BJ, Sternberger LA. Improved visualization of luteinizing hormone releasing hormone pathways by immunocytochemical staining of thick vibratome sections. J Histochem Cytochem 1980; 28: 361-363.
116. De Souza MJ, Lee DK, VanHeest JL, Scheid JL, West SL, Williams NI. Severity of energy-related menstrual disturbances increases in proportion to indices of energy conservation in exercising women. Fertil Steril 2007; 88: 971-975.
117. Gruaz NM, Pierroz DD, Rohner-Jeanrenaud F, Sizonenko PC, Aubert ML. Evidence that neuropeptide Y could represent a neuroendocrine inhibitor of sexual maturation in unfavorable metabolic conditions in the rat. Endocrinology 1993; 133: 1891-1894.
118. Steiner J, LaPaglia N, Kirsteins L, Emanuele M, Emanuele N. The response of the hypothalamic-pituitary-gonadal axis to fasting is modulated by leptin. Endocr Res 2003; 29: 107-117.
119. Gruenewald DA, Matsumoto AM. Reduced gonadotropin-releasing hormone gene expression with fasting in the male rat brain. Endocrinology 1993; 132: 480-482.
120. Judd SJ. Disturbance of the reproductive axis induced by negative energy balance. Reprod Fertil Dev 1998; 10: 65-72.
121. Lin S, Lin EJ, Boey D, Lee NJ, Slack K, During MJ etal. Fasting inhibits the growth and reproductive axes via distinct Y2 and Y4 receptor-mediated pathways. Endocrinology 2007; 148: 2056-2065.
122. Bergendahl M, Perheentupa A, Huhtaniemi I. Starvation-induced suppression of pituitary-testicular function in rats is reversed by pulsatile gonadotropin-releasing hormone substitution. Biol Reprod 1991; 44: 413-419.
123. Mah PM, Wittert GA. Obesity and testicular function. Mol Cell Endocrinol 2010; 316: 180-186.
124. Panter-Brick C, Lotstein DS, Ellison PT. Seasonality of reproductive function and weight loss in rural Nepali women. Hum Reprod 1993; 8: 684-690.
125. Loucks AB, Thuma JR. Luteinizing hormone pulsatility is disrupted at a threshold of energy availability in regularly menstruating women. J Clin Endocrinol Metab 2003; 88: 297-311.
126. Chan JL, Mantzoros CS. Role of leptin in energy-deprivation states: normal human physiology and clinical implications for hypothalamic amenorrhoea and anorexia nervosa. Lancet 2005; 366: 74-85.
127. Warren MP, Chua AT. Exercise-induced amenorrhea and bone health in the adolescent athlete. Ann N Y Acad Sci 2008; 1135: 244-252.
128. Klibanski A, Beitins IZ, Badger T, Little R, McArthur JW. Reproductive function during fasting in men. J Clin Endocrinol Metab 1981; 53: 258-263.
129. Niskanen L, Laaksonen DE, Punnonen K, Mustajoki P, Kaukua J, Rissanen A. Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obes Metab 2004; 6: 208-215.
130. Raposinho PD, Pierroz DD, Broqua P, White RB, Pedrazzini T, Aubert ML. Chronic administration of neuropeptide Y into the lateral ventricle of C57BL/6J male mice produces an obesity syndrome including hyperphagia, hyperleptinemia, insulin resistance, and hypogonadism. Mol Cell Endocrinol 2001; 185: 195-204.
131. Catzeflis C, Pierroz DD, Rohner-Jeanrenaud F, Rivier JE, Sizonenko PC, Aubert ML. Neuropeptide Y administered chronically into the lateral ventricle profoundly inhibits both the gonadotropic and the somatotropic axis in intact adult female rats. Endocrinology 1993; 132: 224-234.
132. Pierroz DD, Catzeflis C, Aebi AC, Rivier JE, Aubert ML. Chronic administration of neuropeptide Y into the lateral ventricle inhibits both the pituitary-testicular axis and growth hormone and insulin-like growth factor I secretion in intact adult male rats. Endocrinology 1996; 137: 3-12.
133. Aubert ML, Pierroz DD, Gruaz NM, d'Alleves V, Vuagnat BA, Pralong FP etal. Metabolic control of sexual function and growth: role of neuropeptide Y and leptin. Mol Cell Endocrinol 1998; 140: 107-113.
134. Pierroz DD, Gruaz NM, d'Alieves V, Aubert ML. Chronic administration of neuropeptide Y into the lateral ventricle starting at 30 days of life delays sexual maturation in the female rat. Neuroendocrinology 1995; 61: 293-300.
135. Kalra SP, Xu B, Dube MG, Moldawer LL, Martin D, Kalra PS. Leptin and ciliary neurotropic factor (CNTF) inhibit fasting-induced suppression of luteinizing hormone release in rats: role of neuropeptide Y. Neurosci Lett 1998; 240: 45-49.
136. Erickson JC, Hollopeter G, Palmiter RD. Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y. Science 1996; 274: 1704-1707.
137. Bergendahl M, Perheentupa A, Huhtaniemi I. Effect of short-term starvation on reproductive hormone gene expression, secretion and receptor levels in male rats. J Endocrinol 1989; 121: 409-417.
138. Kalra SP, Kalra PS. Nutritional infertility: the role of the interconnected hypothalamic neuropeptide Y-galanin-opioid network. Front Neuroendocrinol 1996; 17: 371-401.
139. Guy J, Li S, Pelletier G. Studies on the physiological role and mechanism of action of neuropeptide Y in the regulation of luteinizing hormone secretion in the rat. Regul Pept 1988; 23: 209-216.
140. Sabatino FD, Murnane JM, Hoffman RA, McDonald JK. Distribution of neuropeptide Y-like immunoreactivity in the hypothalamus of the adult golden hamster. J Comp Neurol 1987; 257: 93-104.
141. Leranth C, MacLusky NJ, Shanabrough M, Naftolin F. Immunohistochemical evidence for synaptic connections between pro-opiomelanocortin-immunoreactive axons and LH-RH neurons in the preoptic area of the rat. Brain Res 1988; 449: 167-176.
142. Rondini TA, Baddini SP, Sousa LF, Bittencourt JC, Elias CF. Hypothalamic cocaine- and amphetamine-regulated transcript neurons project to areas expressing gonadotropin releasing hormone immunoreactivity and to the anteroventral periventricular nucleus in male and female rats. Neuroscience 2004; 125: 735-748.
143. Scimonelli T, Medina F, Wilson C, Celis ME. Interaction of alpha-melanotropin (alpha-MSH) and noradrenaline in the median eminence in the control of female sexual behavior. Peptides 2000; 21: 219-223.
144. Gonzalez MI, Celis ME, Hole DR, Wilson CA. Interaction of oestradiol, alpha-melanotropin and noradrenaline within the ventromedial nucleus in the control of female sexual behaviour. Neuroendocrinology 1993; 58: 218-226.
145. Gilbeau PM, Almirez RG, Holaday JW, Smith CG. Opioid effects on plasma concentrations of luteinizing hormone and prolactin in the adult male rhesus monkey. J Clin Endocrinol Metab 1985; 60: 299-305.
146. Leadem CA, Kalra SP. Reversal of beta-endorphin-induced blockade of ovulation and luteinizing hormone surge with prostaglandin E2. Endocrinology 1985; 117: 684-689.
147. Wardlaw SL, Ferin M. Interaction between beta-endorphin and alpha-melanocyte-stimulating hormone in the control of prolactin and luteinizing hormone secretion in the primate. Endocrinology 1990; 126: 2035-2040.
148. Yaswen L, Diehl N, Brennan MB, Hochgeschwender U. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat Med 1999; 5: 1066-1070.
149. Raposinho PD, Castillo E, d'Alleves V, Broqua P, Pralong FP, Aubert ML. Chronic blockade of the melanocortin 4 receptor subtype leads to obesity independently of neuropeptide Y action, with no adverse effects on the gonadotropic and somatotropic axes. Endocrinology 2000; 141: 4419-4427.
150. Hohmann JG, Teal TH, Clifton DK, Davis J, Hruby VJ, Han G etal. Differential role of melanocortins in mediating leptin's central effects on feeding and reproduction. Am J Physiol Regul Integr Comp Physiol 2000; 278: R50-R59.
151. Balthasar N, Mery PF, Magoulas CB, Mathers KE, Martin A, Mollard P etal. Growth hormone-releasing hormone (GHRH) neurons in GHRH-enhanced green fluorescent protein transgenic mice: a ventral hypothalamic network. Endocrinology 2003; 144: 2728-2740.
152. Ho KK, O'Sullivan AJ, Hoffman DM. Metabolic actions of growth hormone in man. Endocr J 1996; 43: S57-S63.
153. Wood TL, Berelowitz M, Gelato MC, Roberts CT, Jr., LeRoith D, Millard WJ etal. Hormonal regulation of rat hypothalamic neuropeptide mRNAs: effect of hypophysectomy and hormone replacement on growth-hormone-releasing factor, somatostatin and the insulin-like growth factors. Neuroendocrinology 1991; 53: 298-305.
154. Uchiyama T, Kaji H, Abe H, Chihara K. Negative regulation of hypothalamic growth hormone-releasing factor messenger ribonucleic acid by growth hormone and insulin-like growth factor I. Neuroendocrinology 1994; 59: 441-450.
155. Chomczynski P, Downs TR, Frohman LA. Feedback regulation of growth hormone (GH)-releasing hormone gene expression by GH in rat hypothalamus. Mol Endocrinol 1988; 2: 236-241.
156. Luque RM, Park S, Kineman RD. Severity of the catabolic condition differentially modulates hypothalamic expression of growth hormone-releasing hormone in the fasted mouse: potential role of neuropeptide Y and corticotropin-releasing hormone. Endocrinology 2007; 148: 300-309.
157. LaPaglia N, Steiner J, Kirsteins L, Emanuele M, Emanuele N. Leptin alters the response of the growth hormone releasing factor-growth hormone - insulin-like growth factor-I axis to fasting. J Endocrinol 1998; 159: 79-83.
158. Park S, Sohn S, Kineman RD. Fasting-induced changes in the hypothalamic-pituitary-GH axis in the absence of GH expression: lessons from the spontaneous dwarf rat. J Endocrinol 2004; 180: 369-378.
159. Park S, Peng XD, Frohman LA, Kineman RD. Expression analysis of hypothalamic and pituitary components of the growth hormone axis in fasted and streptozotocin-treated neuropeptide Y (NPY)-intact (NPY+/+) and NPY-knockout (NPY-/-) mice. Neuroendocrinology 2005; 81: 360-371.
160. Tannenbaum GS, Rorstad O, Brazeau P. Effects of prolonged food deprivation on the ultradian growth hormone rhythm and immunoreactive somatostatin tissue levels in the rat. Endocrinology 1979; 104: 1733-1738.
161. Tannenbaum GS, Guyda HJ, Posner BI. Insulin-like growth factors: a role in growth hormone negative feedback and body weight regulation via brain. Science 1983; 220: 77-79.
162. Murphy LJ, Seneviratne C, Moreira P, Reid RE. Enhanced expression of insulin-like growth factor-binding protein-I in the fasted rat: the effects of insulin and growth hormone administration. Endocrinology 1991; 128: 689-696.
163. Bruno JF, Olchovsky D, White JD, Leidy JW, Song J, Berelowitz M. Influence of food deprivation in the rat on hypothalamic expression of growth hormone-releasing factor and somatostatin. Endocrinology 1990; 127: 2111-2116.
164. Janowski BA, Ling NC, Giustina A, Wehrenberg WB. Hypothalamic regulation of growth hormone secretion during food deprivation in the rat. Life Sci 1993; 52: 981-987.
165. Carro E, Senaris R, Considine RV, Casanueva FF, Dieguez C. Regulation of in vivo growth hormone secretion by leptin. Endocrinology 1997; 138: 2203-2206.
166. Schindler WJ, Hutchins MO, Septimus EJ. Growth hormone secretion and control in the mouse. Endocrinology 1972; 91: 483-490.
167. Sugihara H, Emoto N, Shibasaki T, Minami S, Wakabayashi I. Increased pituitary growth hormone-releasing factor (GRF) receptor messenger ribonucleic acid expression in food-deprived rats. Brain Res 1996; 742: 355-358.
168. McKnight BJ, Goddard C. The effect of food restriction on circulating insulin-like growth factor-I in mice divergently selected for high or low protein or fat to body mass ratios. Comp Biochem Physiol 1989; 92: 565-569.
169. Underwood LE, Clemmons DR, Maes M, D'Ercole AJ, Ketelslegers JM. Regulation of somatomedin-C/insulin-like growth factor I by nutrients. Horm Res 1986; 24: 166-176.
170. Vance ML, Hartman ML, Thorner MO. Growth hormone and nutrition. Horm Res 1992; 38(Suppl. 1): 85-88.
171. Ohashi S, Kaji H, Abe H, Chihara K. Effect of fasting and growth hormone (GH) administration on GH receptor (GHR) messenger ribonucleic acid (mRNA) and GH-binding protein (GHBP) mRNA levels in male rats. Life Sci 1995; 57: 1655-1666.
172. Bornfeldt KE, Arnqvist HJ, Enberg B, Mathews LS, Norstedt G. Regulation of insulin-like growth factor-I and growth hormone receptor gene expression by diabetes and nutritional state in rat tissues. J Endocrinol 1989; 122: 651-656.
173. Inagaki T, Lin VY, Goetz R, Mohammadi M, Mangelsdorf DJ, Kliewer SA. Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab 2008; 8: 77-83.
174. Soliman AT, ElZalabany MM, Salama M, Ansari BM. Serum leptin concentrations during severe protein-energy malnutrition: correlation with growth parameters and endocrine function. Metabolism 2000; 49: 819-825.
175. Rosen CJ, Ackert-Bicknell CL, Adamo ML, Shultz KL, Rubin J, Donahue LR etal. Congenic mice with low serum IGF-I have increased body fat, reduced bone mineral density, and an altered osteoblast differentiation program. Bone 2004; 35: 1046-1058.
176. Kamel HK, Maas D, Duthie EH Jr. Role of hormones in the pathogenesis and management of sarcopenia. Drugs Aging 2002; 19: 865-877.
177. Schwartz MW, Sipols A, Grubin CE, Baskin DG. Differential effect of fasting on hypothalamic expression of genes encoding neuropeptide Y, galanin, and glutamic acid decarboxylase. Brain Res Bull 1993; 31: 361-367.
178. Grove KL, Chen P, Koegler FH, Schiffmaker A, Susan Smith M, Cameron JL. Fasting activates neuropeptide Y neurons in the arcuate nucleus and the paraventricular nucleus in the rhesus macaque. Brain Res Mol Brain Res 2003; 113: 133-138.
179. Sahu A, Kalra PS, Kalra SP. Food deprivation and ingestion induce reciprocal changes in neuropeptide Y concentrations in the paraventricular nucleus. Peptides 1988; 9: 83-86.
180. Raposinho PD, White RB, Aubert ML. The melanocortin agonist melanotan-II reduces the orexigenic and adipogenic effects of neuropeptide Y (NPY) but does not affect the NPY-driven suppressive effects on the gonadotropic and somatotropic axes in the male rat. J Neuroendocrinol 2003; 15: 173-181.
181. Silva JE. The thermogenic effect of thyroid hormone and its clinical implications. Ann Intern Med 2003; 139: 205-213.
182. Al-Adsani H, Hoffer LJ, Silva JE. Resting energy expenditure is sensitive to small dose changes in patients on chronic thyroid hormone replacement. J Clin Endocrinol Metab 1997; 82: 1118-1125.
183. Boivin M, Camirand A, Carli F, Hoffer LJ, Silva JE. Uncoupling protein-2 and -3 messenger ribonucleic acids in adipose tissue and skeletal muscle of healthy males: variability, factors affecting expression, and relation to measures of metabolic rate. J Clin Endocrinol Metab 2000; 85: 1975-1983.
184. Liverini G, Iossa S, Barletta A. Relationship between resting metabolism and hepatic metabolism: effect of hypothyroidism and 24 hours fasting. Horm Res 1992; 38: 154-159.
185. Bianco AC, Maia AL, da Silva WS, Christoffolete MA. Adaptive activation of thyroid hormone and energy expenditure. Biosci Rep 2005; 25: 191-208.
186. Bianco AC, Silva JE. Intracellular conversion of thyroxine to triiodothyronine is required for the optimal thermogenic function of brown adipose tissue. J Clin Invest 1987; 79: 295-300.
187. Seydoux J, Giacobino JP, Girardier L. Impaired metabolic response to nerve stimulation in brown adipose tissue of hypothyroid rats. Mol Cell Endocrinol 1982; 25: 213-226.
188. Iossa S, Mollica MP, Lionetti L, Barletta A, Liverini G. Effect of a high-fat diet on energy balance and thermic effect of food in hypothyroid rats. Eur J Endocrinol 1997; 136: 309-315.
189. Iossa S, Mollica MP, Lionetti L, Barletta A, Liverini G. Hepatic mitochondrial respiration and transport of reducing equivalents in rats fed an energy dense diet. Int J Obes Relat Metab Disord 1995; 19: 539-543.
190. Liverini G, Iossa S, Lionetti L, Mollica MP, Barletta A. Sympathetically-mediated thermogenic response to food in rats. Int J Obes Relat Metab Disord 1995; 19: 87-91.
191. Iossa S, Mollica MP, Lionetti L, Barletta A, Liverini G. Energy balance and liver respiratory activity in rats fed on an energy-dense diet. Br J Nutr 1997; 77: 99-105.
192. Mollica MP, Iossa S, Liverini G, Soboll S. Stimulation of oxygen consumption following addition of lipid substrates in liver and skeletal muscle from rats fed a high-fat diet. Metabolism 1999; 48: 1230-1235.
193. Rothwell NJ, Saville ME, Stock MJ, Wyllie MG. Catecholamine and thyroid hormone influence on brown fat Na+, K+-ATPase activity and thermogenesis in the rat. Horm Metab Res 1982; 14: 261-265.
194. Lopez M, Varela L, Vazquez MJ, Rodriguez-Cuenca S, Gonzalez CR, Velagapudi VR etal. Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance. Nat Med 2010; 16: 1001-1008.
195. van den Beld AW, Visser TJ, Feelders RA, Grobbee DE, Lamberts SW. Thyroid hormone concentrations, disease, physical function, and mortality in elderly men. J Clin Endocrinol Metab 2005; 90: 6403-6409.
196. Diekman MJ, Romijn JA, Endert E, Sauerwein H, Wiersinga WM. Thyroid hormones modulate serum leptin levels: observations in thyrotoxic and hypothyroid women. Thyroid 1998; 8: 1081-1086.
197. Iglesias P, Alvarez Fidalgo P, Codoceo R, Diez JJ. Serum concentrations of adipocytokines in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function. Clin Endocrinol (Oxf) 2003; 59: 621-629.
198. Kong WM, Martin NM, Smith KL, Gardiner JV, Connoley IP, Stephens DA etal. Triiodothyronine stimulates food intake via the hypothalamic ventromedial nucleus independent of changes in energy expenditure. Endocrinology 2004; 145: 5252-5258.
199. Luo L, MacLean DB. Effects of thyroid hormone on food intake, hypothalamic Na/K ATPase activity and ATP content. Brain Res 2003; 973: 233-239.
200. Oppenheimer JH, Schwartz HL, Lane JT, Thompson MP. Functional relationship of thyroid hormone-induced lipogenesis, lipolysis, and thermogenesis in the rat. J Clin Invest 1991; 87: 125-132.
201. Iossa S, Lionetti L, Mollica MP, Crescenzo R, Barletta A, Liverini G. Fat balance and serum leptin concentrations in normal, hypothyroid, and hyperthyroid rats. Int J Obes Relat Metab Disord 2001; 25: 417-425.
202. Mooradian AD. Age-related differences in body weight loss in response to altered thyroidal status. Exp Gerontol 1990; 25: 29-35.
203. Freake HC, Oppenheimer JH. Thermogenesis and thyroid function. Annu Rev Nutr 1995; 15: 263-291.
204. Goodridge AG. Regulation of malic enzyme synthesis by thyroid hormone and glucagon: inhibitor and kinetic experiments. Mol Cell Endocrinol 1978; 11: 19-29.
205. Miksicek RJ, Towle HC. Changes in the rates of synthesis and messenger RNA levels of hepatic glucose-6-phosphate and 6-phosphogluconate dehydrogenases following induction by diet or thyroid hormone. J Biol Chem 1982; 257: 11829-11835.
206. Bianco AC, Silva JE. Optimal response of key enzymes and uncoupling protein to cold in BAT depends on local T3 generation. Am J Physiol 1987; 253: E255-E263.
207. Bianco AC, Carvalho SD, Carvalho CR, Rabelo R, Moriscot AS. Thyroxine 5′-deiodination mediates norepinephrine-induced lipogenesis in dispersed brown adipocytes. Endocrinology 1998; 139: 571-578.
208. Carvalho SD, Negrao N, Bianco AC. Hormonal regulation of malic enzyme and glucose-6-phosphate dehydrogenase in brown adipose tissue. Am J Physiol 1993; 264: E874-E881.
209. Weetman AP. Graves' disease. N Engl J Med 2000; 343: 1236-1248.
210. Loeb JN. Metabolic changes in hypothyroidism. In: Braveman LE, Utiger RD (eds). The Thyroid. Lippincott: Philadelphia, PA, 1991, pp. 1064-1071.
211. Freitas FR, Capelo LP, O'Shea PJ, Jorgetti V, Moriscot AS, Scanlan TS etal. The thyroid hormone receptor beta-specific agonist GC-1 selectively affects the bone development of hypothyroid rats. J Bone Miner Res 2005; 20: 294-304.
212. Natsui K, Tanaka K, Suda M, Yasoda A, Sakuma Y, Ozasa A etal. High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass. Osteoporos Int 2006; 17: 105-108.
213. Curtis JR, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V etal. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 2006; 55: 420-426.
214. Peeke PM, Chrousos GP. Hypercortisolism and obesity. Ann N Y Acad Sci 1995; 771: 665-676.
215. Asarian L, Geary N. Modulation of appetite by gonadal steroid hormones. Philos Trans R Soc Lond B Biol Sci 2006; 361: 1251-1263.
216. Clegg DJ, Brown LM, Woods SC, Benoit SC. Gonadal hormones determine sensitivity to central leptin and insulin. Diabetes 2006; 55: 978-987.
217. Geary N, Lovejoy JC. Sex differences in energy metabolism, obesity and eating behavior. In: Becker JB, Berkley KJ, Geary N, Hampson E, Herman JP, Young EA (eds). Sex Differences in the Brain. Oxford University Press: Oxford, NY, 2008, pp. 253-274.
218. Lovejoy JC, Sainsbury A. Sex differences in obesity and the regulation of energy homeostasis. Obes Rev 2009; 10: 154-167.
219. Poehlman ET. Menopause, energy expenditure, and body composition. Acta Obstet Gynecol Scand 2002; 81: 603-611.
220. Lovejoy JC, Champagne CM, de Jonge L, Xie H, Smith SR. Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes (Lond) 2008; 32: 949-958.
221. Isken F, Pfeiffer AF, Nogueiras R, Osterhoff MA, Ristow M, Thorens B etal. Deficiency of glucose-dependent insulinotropic polypeptide receptor prevents ovariectomy-induced obesity in mice. Am J Physiol Endocrinol Metab 2008; 295: E350-E355.
222. Zengin A, Zhang L, Herzog H, Baldock PA, Sainsbury A. Neuropeptide Y and sex hormone interactions in humoral and neuronal regulation of bone and fat. Trends Endocrinol Metab 2010; 21: 411-418.
223. Mattiasson I, Rendell M, Tornquist C, Jeppsson S, Hulthen UL. Effects of estrogen replacement therapy on abdominal fat compartments as related to glucose and lipid metabolism in early postmenopausal women. Horm Metab Res 2002; 34: 583-588.
224. Blouin K, Despres JP, Couillard C, Tremblay A, Prud'homme D, Bouchard C etal. Contribution of age and declining androgen levels to features of the metabolic syndrome in men. Metabolism 2005; 54: 1034-1040.
225. Marin P, Holmang S, Gustafsson C, Jonsson L, Kvist H, Elander A etal. Androgen treatment of abdominally obese men. Obes Res 1993; 1: 245-251.
226. Lovejoy JC, Bray GA, Greeson CS, Klemperer M, Morris J, Partington C etal. Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases abdominal fat in obese, older men. Int J Obes Relat Metab Disord 1995; 19: 614-624.
227. Mudali S, Dobs AS. Effects of testosterone on body composition of the aging male. Mech Ageing Dev 2004; 125: 297-304.
228. Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ etal. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 2005; 90: 1502-1510.
229. Kawai M, Rosen CJ. The IGF-I regulatory system and its impact on skeletal and energy homeostasis. J Cell Biochem 2010; 111: 14-19.
230. Adamo ML, Farrar RP. Resistance training, and IGF involvement in the maintenance of muscle mass during the aging process. Ageing Res Rev 2006; 5: 310-331.
231. Mauras N, Haymond MW. Are the metabolic effects of GH and IGF-I separable? Growth Horm IGF Res 2005; 15: 19-27.
232. Hunter GR, Byrne NM, Sirikul B, Fernandez JR, Zuckerman PA, Darnell BE etal. Resistance training conserves fat-free mass and resting energy expenditure following weight loss. Obesity (Silver Spring) 2008; 16: 1045-1051.
233. Borst SE, De Hoyos DV, Garzarella L, Vincent K, Pollock BH, Lowenthal DT etal. Effects of resistance training on insulin-like growth factor-I and IGF binding proteins. Med Sci Sports Exerc 2001; 33: 648-653.
234. Maddalozzo GF, Snow CM. High intensity resistance training: effects on bone in older men and women. Calcif Tissue Int 2000; 66: 399-404.
235. Burke DG, Candow DG, Chilibeck PD, MacNeil LG, Roy BD, Tarnopolsky MA etal. Effect of creatine supplementation and resistance-exercise training on muscle insulin-like growth factor in young adults. Int J Sport Nutr Exerc Metab 2008; 18: 389-398.
236. Olszanecka-Glinianowicz M, Zahorska-Markiewicz B, Kocelak P, Janowska J, Semik-Grabarczyk E. The effect of weight reduction on plasma concentrations of ghrelin and insulin-like growth factor 1 in obese women. Endokrynol Pol 2008; 59: 301-304.
237. Scott WR, Roux-en BRL. Y gastric bypass and laparoscopic sleeve gastrectomy: understanding weight loss and improvements in type 2 diabetes after bariatric surgery. Am J Physiol Regul Integr Comp Physiol 2011; 301: R15-R27.
238. Pfluger PT, Kampe J, Castaneda TR, Vahl T, D'Alessio DA, Kruthaupt T etal. Effect of human body weight changes on circulating levels of peptide YY and peptide YY3-36. J Clin Endocrinol Metab 2007; 92: 583-588.
239. Asakawa A, Inui A, Kaga T, Yuzuriha H, Nagata T, Ueno N etal. Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 2001; 120: 337-345.
240. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K etal. A role for ghrelin in the central regulation of feeding. Nature 2001; 409: 194-198.
241. Batterham RL, Heffron H, Kapoor S, Chivers JE, Chandarana K, Herzog H etal. Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab 2006; 4: 223-233.
242. Lanfranco F, Motta G, Baldi M, Gasco V, Grottoli S, Benso A etal. Ghrelin and anterior pituitary function. Front Horm Res 2010; 38: 206-211.
243. Boey D, Lin S, Enriquez RF, Lee NJ, Slack K, Couzens M etal. PYY transgenic mice are protected against diet-induced and genetic obesity. Neuropeptides 2008; 42: 19-30.
244. Boey D, Lin S, Karl T, Baldock P, Lee N, Enriquez R etal. Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity. Diabetologia 2006; 49: 1360-1370.
245. Manore MM, Kam LC, Loucks AB. The female athlete triad: components, nutrition issues, and health consequences. J Sports Sci 2007; 25(Suppl. 1): S61-S71.
246. Mayer LE, Klein DA, Black E, Attia E, Shen W, Mao X etal. Adipose tissue distribution after weight restoration and weight maintenance in women with anorexia nervosa. Am J Clin Nutr 2009; 90: 1132-1137.
247. Hunter GR, Brock DW, Byrne NM, Chandler-Laney PC, Del Corral P, Gower BA. Exercise training prevents regain of visceral fat for 1 year following weight loss. Obesity (Silver Spring) 2010; 18: 690-695.
248. Mojtahedi MC, Thorpe MP, Karampinos DC, Johnson CL, Layman DK, Georgiadis JG etal. The effects of a higher protein intake during energy restriction on changes in body composition and physical function in older women. J Gerontol A Biol Sci Med Sci 2011; 66: 1218-1225.
249. Treuth MS, Hunter GR, Kekes-Szabo T, Weinsier RL, Goran MI, Berland L. Reduction in intra-abdominal adipose tissue after strength training in older women. J Appl Physiol 1995; 78: 1425-1431.
250. Delbridge E, Proietto J. State of the science: VLED (very low energy diet) for obesity. Asia Pac J Clin Nutr 2006; 15(Suppl.): 49-54.
251. Chearskul S, Delbridge E, Shulkes A, Proietto J, Kriketos A. Effect of weight loss and ketosis on postprandial cholecystokinin and free fatty acid concentrations. Am J Clin Nutr 2008; 87: 1238-1246.
252. Sweeney ME, Hill JO, Heller PA, Baney R, DiGirolamo M. Severe vs moderate energy restriction with and without exercise in the treatment of obesity: efficiency of weight loss. Am J Clin Nutr 1993; 57: 127-134.
253. Garthe I, Raastad T, Refsnes PE, Koivisto A, Sundgot-Borgen J. Effect of two different weight-loss rates on body composition and strength and power-related performance in elite athletes. Int J Sport Nutr Exerc Metab 2011; 21: 97-104.
254. Schneider BE, Mun EC. Surgical management of morbid obesity. Diabetes Care 2005; 28: 475-480.
255. Blackburn GL. Solutions in weight control: lessons from gastric surgery. Am J Clin Nutr 2005; 82: 248S-252S.
256. Everson G, Kelsberg G, Nashelsky J, Mott T. Clinical inquiries. How effective is gastric bypass for weight loss? J Fam Pract 2004; 53: 914-918.
257. Flancbaum L, Choban PS, Bradley LR, Burge JC. Changes in measured resting energy expenditure after Roux-en-Y gastric bypass for clinically severe obesity. Surgery 1997; 122: 943-949.
258. Olbers T, Bjorkman S, Lindroos A, Maleckas A, Lonn L, Sjostrom L etal. Body composition, dietary intake, and energy expenditure after laparoscopic Roux-en-Y gastric bypass and laparoscopic vertical banded gastroplasty: a randomized clinical trial. Ann Surg 2006; 244: 715-722.